The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-03-21

AUTHORS

Sang Joon Shin, Joong Bae Ahn, Hye Jin Choi, Byoung Chul Cho, Hei-Cheul Jeung, Sun Young Rha, Hyun Cheol Chung, Jae Kyung Roh

ABSTRACT

PurposeSince the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin.MethodsThirty-three MCRC patients participated in this study and received an oral dose of 1,000 mg/m2 capecitabine twice daily on days 1–14 and a dose of 100 mg/m2 irinotecan infused over 90 min on days 1 and 8, every 3 weeks.ResultsThe overall response rate in intent-to-treat was 33.3% (95% CI, 21.5–58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 patients (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8–8.6 months). After a median follow-up time of 12 months, nine patients (27.3%) were still alive with metastatic disease. The median response duration for all patients was 6.7 months (95% CI, 3.9–9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0–15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 neutropenia, however, occurred in eight (24%) patients and grade 3 anemia was seen in one patient (3%). The most common (grade 3/4) non-hematological toxicity was diarrhea (15%) and the other severe grade 3/4 toxicities included nausea/vomiting in one patient (3%), stomatitis in one patient (3%), hand-foot syndrome in one patient (3%). ConclusionsThe combination of capecitabine and irinotecan is an effective and well-tolerated regimen for second-line treatment of metastatic colorectal cancer. However, further phase III trials are required to clarify its use in the treatment of metastastic colorectal cancer patients who have been pretreated with 5-fluorouracil and oxaliplatin. More... »

PAGES

75-81

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-007-0447-2

DOI

http://dx.doi.org/10.1007/s00280-007-0447-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036946481

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17375304


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Irinotecan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organoplatinum Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxaliplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shin", 
        "givenName": "Sang Joon", 
        "id": "sg:person.011321544242.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011321544242.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ahn", 
        "givenName": "Joong Bae", 
        "id": "sg:person.010673374672.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673374672.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Choi", 
        "givenName": "Hye Jin", 
        "id": "sg:person.01363365111.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363365111.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cho", 
        "givenName": "Byoung Chul", 
        "id": "sg:person.013035643562.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013035643562.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jeung", 
        "givenName": "Hei-Cheul", 
        "id": "sg:person.01276364570.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rha", 
        "givenName": "Sun Young", 
        "id": "sg:person.01036404665.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chung", 
        "givenName": "Hyun Cheol", 
        "id": "sg:person.016554426212.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea", 
          "id": "http://www.grid.ac/institutes/grid.15444.30", 
          "name": [
            "Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roh", 
        "givenName": "Jae Kyung", 
        "id": "sg:person.0767622633.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6601676", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008836493", 
          "https://doi.org/10.1038/sj.bjc.6601676"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042162349", 
          "https://doi.org/10.1038/sj.bjc.6603095"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-03-21", 
    "datePublishedReg": "2007-03-21", 
    "description": "PurposeSince the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin.MethodsThirty-three MCRC patients participated in this study and received an oral dose of 1,000\u00a0mg/m2 capecitabine twice daily on days\u00a01\u201314 and a dose of 100\u00a0mg/m2 irinotecan infused over 90\u00a0min on days\u00a01 and 8, every 3\u00a0weeks.ResultsThe overall response rate in intent-to-treat was 33.3% (95% CI, 21.5\u201358.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 patients (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7\u00a0months (95% CI, 4.8\u20138.6\u00a0months). After a median follow-up time of 12\u00a0months, nine patients (27.3%) were still alive with metastatic disease. The median response duration for all patients was 6.7\u00a0months (95% CI, 3.9\u20139.5\u00a0months) and the median overall survival was 13.4\u00a0months (95% CI, 11.0\u201315.8\u00a0months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 neutropenia, however, occurred in eight (24%) patients and grade 3 anemia was seen in one patient (3%). The most common (grade 3/4) non-hematological toxicity was diarrhea (15%) and the other severe grade 3/4 toxicities included nausea/vomiting in one patient (3%), stomatitis in one patient (3%), hand-foot syndrome in one patient (3%). ConclusionsThe combination of capecitabine and irinotecan is an effective and well-tolerated regimen for second-line treatment of metastatic colorectal cancer. However, further phase III trials are required to clarify its use in the treatment of metastastic colorectal cancer patients who have been pretreated with 5-fluorouracil and oxaliplatin.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-007-0447-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "61"
      }
    ], 
    "keywords": [
      "metastatic colorectal cancer", 
      "combination of capecitabine", 
      "second-line treatment", 
      "colorectal cancer", 
      "common non-hematological toxicity", 
      "severe grade 3/4 toxicities", 
      "metastatic colorectal patients", 
      "median response duration", 
      "grade 3/4 neutropenia", 
      "grade 3 anemia", 
      "grade 3/4 toxicities", 
      "median overall survival", 
      "non-hematological toxicities", 
      "hand-foot syndrome", 
      "first-line treatment", 
      "phase III trials", 
      "colorectal cancer patients", 
      "overall response rate", 
      "m2 capecitabine", 
      "m2 irinotecan", 
      "nausea/", 
      "colorectal patients", 
      "mCRC patients", 
      "median follow", 
      "disease stabilization", 
      "III trials", 
      "complete response", 
      "partial response", 
      "metastatic disease", 
      "overall survival", 
      "median time", 
      "oral dose", 
      "cancer patients", 
      "response duration", 
      "patients", 
      "capecitabine", 
      "response rate", 
      "survival rate", 
      "irinotecan", 
      "oxaliplatin", 
      "cancer", 
      "months", 
      "ConclusionsThe combination", 
      "treatment", 
      "dose", 
      "toxicity", 
      "days", 
      "myelosuppression", 
      "neutropenia", 
      "regimen", 
      "diarrhea", 
      "anemia", 
      "syndrome", 
      "follow", 
      "disease", 
      "progression", 
      "trials", 
      "weeks", 
      "response", 
      "survival", 
      "promising results", 
      "duration", 
      "treat", 
      "rate", 
      "combination", 
      "min", 
      "study", 
      "time", 
      "intent", 
      "use", 
      "results", 
      "stabilization"
    ], 
    "name": "The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer", 
    "pagination": "75-81", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036946481"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-007-0447-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17375304"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-007-0447-2", 
      "https://app.dimensions.ai/details/publication/pub.1036946481"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_443.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-007-0447-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0447-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0447-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0447-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-007-0447-2'


 

This table displays all metadata directly associated to this object as RDF triples.

275 TRIPLES      22 PREDICATES      121 URIs      111 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-007-0447-2 schema:about N2e27185d6b4c41d7a2955adfb932564a
2 N34130930a0834dd0a48f8a29a5ccaa14
3 N3d020c7fb8d54fd28f5594bef0f1ec6b
4 N42eb39b3ec5e4d52b8bdf8c0a396d0e9
5 N4f68a8e067ac4374afb0dce15855cfe0
6 N63c8144048b44d9e8db4ac8dcfcc7805
7 N64cbf53231b24ebaadd066d2167a1ccb
8 N666bd642d1814970aed1d712c222f661
9 N71e30a8a5e464ffeab06793b550e2f36
10 N73a341a17556494eb024d056acd76a05
11 N802728dd472c49b1834e63a427686ce2
12 N850808821709430a96a4603929d232dc
13 N863f7db3a7a74479b13a7a3d2d2e12ad
14 N8cb21053e270487bafd2bacb42bbc169
15 Nb14887656f664b8291f9770660e31c1b
16 Nc8f3195963024d01a8e4289493687711
17 Ncb526200df9a417b85b347c299bc2c0d
18 Ndc6df41e6e1d4c398dd2d86472712313
19 Ndc7e52ed74d149a28155f5bcf3e1571b
20 Nddc70f1c566b4a87bd82130d66125d72
21 Ne02ba832a3364351a43b08bd82e9375c
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N8b118759f3e2411cb0306714287bbaee
25 schema:citation sg:pub.10.1038/sj.bjc.6601676
26 sg:pub.10.1038/sj.bjc.6603095
27 schema:datePublished 2007-03-21
28 schema:datePublishedReg 2007-03-21
29 schema:description PurposeSince the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin.MethodsThirty-three MCRC patients participated in this study and received an oral dose of 1,000 mg/m2 capecitabine twice daily on days 1–14 and a dose of 100 mg/m2 irinotecan infused over 90 min on days 1 and 8, every 3 weeks.ResultsThe overall response rate in intent-to-treat was 33.3% (95% CI, 21.5–58.3%), including one complete response (3.0%) and ten partial responses (30.3%); 12 patients (36.4%) had disease stabilization and only 9 (27.3%) progressed. The median time to progression was 6.7 months (95% CI, 4.8–8.6 months). After a median follow-up time of 12 months, nine patients (27.3%) were still alive with metastatic disease. The median response duration for all patients was 6.7 months (95% CI, 3.9–9.5 months) and the median overall survival was 13.4 months (95% CI, 11.0–15.8 months) with a 1-year survival rate of 55.4%. Myelosuppression was commonly observed; NCI-CTC (v 2.0) grade 3/4 neutropenia, however, occurred in eight (24%) patients and grade 3 anemia was seen in one patient (3%). The most common (grade 3/4) non-hematological toxicity was diarrhea (15%) and the other severe grade 3/4 toxicities included nausea/vomiting in one patient (3%), stomatitis in one patient (3%), hand-foot syndrome in one patient (3%). ConclusionsThe combination of capecitabine and irinotecan is an effective and well-tolerated regimen for second-line treatment of metastatic colorectal cancer. However, further phase III trials are required to clarify its use in the treatment of metastastic colorectal cancer patients who have been pretreated with 5-fluorouracil and oxaliplatin.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N95305764ce544dbab930d377de01fd35
34 Nb785d09a7db64ff28780b90dae119b21
35 sg:journal.1088364
36 schema:keywords ConclusionsThe combination
37 III trials
38 anemia
39 cancer
40 cancer patients
41 capecitabine
42 colorectal cancer
43 colorectal cancer patients
44 colorectal patients
45 combination
46 combination of capecitabine
47 common non-hematological toxicity
48 complete response
49 days
50 diarrhea
51 disease
52 disease stabilization
53 dose
54 duration
55 first-line treatment
56 follow
57 grade 3 anemia
58 grade 3/4 neutropenia
59 grade 3/4 toxicities
60 hand-foot syndrome
61 intent
62 irinotecan
63 m2 capecitabine
64 m2 irinotecan
65 mCRC patients
66 median follow
67 median overall survival
68 median response duration
69 median time
70 metastatic colorectal cancer
71 metastatic colorectal patients
72 metastatic disease
73 min
74 months
75 myelosuppression
76 nausea/
77 neutropenia
78 non-hematological toxicities
79 oral dose
80 overall response rate
81 overall survival
82 oxaliplatin
83 partial response
84 patients
85 phase III trials
86 progression
87 promising results
88 rate
89 regimen
90 response
91 response duration
92 response rate
93 results
94 second-line treatment
95 severe grade 3/4 toxicities
96 stabilization
97 study
98 survival
99 survival rate
100 syndrome
101 time
102 toxicity
103 treat
104 treatment
105 trials
106 use
107 weeks
108 schema:name The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
109 schema:pagination 75-81
110 schema:productId N7b3c04747b83414db4250a18795767ef
111 Nd9fa275805bb4681a9b1948cb88f2ef6
112 Ne9e492226ed9448d9de6290ab76fbdd7
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036946481
114 https://doi.org/10.1007/s00280-007-0447-2
115 schema:sdDatePublished 2022-05-20T07:24
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher Nb48a9114abfe45579be2e92cf6408342
118 schema:url https://doi.org/10.1007/s00280-007-0447-2
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N0a610faf0a114b99ad82bd3c4130888e rdf:first sg:person.01276364570.14
123 rdf:rest Nb958f6886b5043c0be99baf89520f857
124 N113959a089714a17adc76912f240de18 rdf:first sg:person.013035643562.16
125 rdf:rest N0a610faf0a114b99ad82bd3c4130888e
126 N2e27185d6b4c41d7a2955adfb932564a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 N34130930a0834dd0a48f8a29a5ccaa14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Capecitabine
131 rdf:type schema:DefinedTerm
132 N3d020c7fb8d54fd28f5594bef0f1ec6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Aged
134 rdf:type schema:DefinedTerm
135 N42eb39b3ec5e4d52b8bdf8c0a396d0e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Adenocarcinoma
137 rdf:type schema:DefinedTerm
138 N46b3f710359440fa817e02ca3ba6e3f8 rdf:first sg:person.0767622633.82
139 rdf:rest rdf:nil
140 N4f68a8e067ac4374afb0dce15855cfe0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Disease Progression
142 rdf:type schema:DefinedTerm
143 N508f33a70cbf4d7ba9171169a64d7bda rdf:first sg:person.016554426212.74
144 rdf:rest N46b3f710359440fa817e02ca3ba6e3f8
145 N63c8144048b44d9e8db4ac8dcfcc7805 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Deoxycytidine
147 rdf:type schema:DefinedTerm
148 N64cbf53231b24ebaadd066d2167a1ccb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Middle Aged
150 rdf:type schema:DefinedTerm
151 N666bd642d1814970aed1d712c222f661 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adult
153 rdf:type schema:DefinedTerm
154 N71e30a8a5e464ffeab06793b550e2f36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Antineoplastic Combined Chemotherapy Protocols
156 rdf:type schema:DefinedTerm
157 N73a341a17556494eb024d056acd76a05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Oxaliplatin
159 rdf:type schema:DefinedTerm
160 N7b3c04747b83414db4250a18795767ef schema:name dimensions_id
161 schema:value pub.1036946481
162 rdf:type schema:PropertyValue
163 N802728dd472c49b1834e63a427686ce2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Fluorouracil
165 rdf:type schema:DefinedTerm
166 N850808821709430a96a4603929d232dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Colorectal Neoplasms
168 rdf:type schema:DefinedTerm
169 N863f7db3a7a74479b13a7a3d2d2e12ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Treatment Outcome
171 rdf:type schema:DefinedTerm
172 N8b118759f3e2411cb0306714287bbaee rdf:first sg:person.011321544242.27
173 rdf:rest Nea1da0bb7dd94765822fa66a990472aa
174 N8cb21053e270487bafd2bacb42bbc169 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Camptothecin
176 rdf:type schema:DefinedTerm
177 N95305764ce544dbab930d377de01fd35 schema:volumeNumber 61
178 rdf:type schema:PublicationVolume
179 Nb10e39c2d6364227a9adfedfcda1141d rdf:first sg:person.01363365111.85
180 rdf:rest N113959a089714a17adc76912f240de18
181 Nb14887656f664b8291f9770660e31c1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Salvage Therapy
183 rdf:type schema:DefinedTerm
184 Nb48a9114abfe45579be2e92cf6408342 schema:name Springer Nature - SN SciGraph project
185 rdf:type schema:Organization
186 Nb785d09a7db64ff28780b90dae119b21 schema:issueNumber 1
187 rdf:type schema:PublicationIssue
188 Nb958f6886b5043c0be99baf89520f857 rdf:first sg:person.01036404665.54
189 rdf:rest N508f33a70cbf4d7ba9171169a64d7bda
190 Nc8f3195963024d01a8e4289493687711 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Male
192 rdf:type schema:DefinedTerm
193 Ncb526200df9a417b85b347c299bc2c0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Neoplasm Metastasis
195 rdf:type schema:DefinedTerm
196 Nd9fa275805bb4681a9b1948cb88f2ef6 schema:name pubmed_id
197 schema:value 17375304
198 rdf:type schema:PropertyValue
199 Ndc6df41e6e1d4c398dd2d86472712313 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Female
201 rdf:type schema:DefinedTerm
202 Ndc7e52ed74d149a28155f5bcf3e1571b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Survival Rate
204 rdf:type schema:DefinedTerm
205 Nddc70f1c566b4a87bd82130d66125d72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Irinotecan
207 rdf:type schema:DefinedTerm
208 Ne02ba832a3364351a43b08bd82e9375c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Organoplatinum Compounds
210 rdf:type schema:DefinedTerm
211 Ne9e492226ed9448d9de6290ab76fbdd7 schema:name doi
212 schema:value 10.1007/s00280-007-0447-2
213 rdf:type schema:PropertyValue
214 Nea1da0bb7dd94765822fa66a990472aa rdf:first sg:person.010673374672.49
215 rdf:rest Nb10e39c2d6364227a9adfedfcda1141d
216 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
217 schema:name Medical and Health Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
220 schema:name Oncology and Carcinogenesis
221 rdf:type schema:DefinedTerm
222 sg:journal.1088364 schema:issn 0344-5704
223 1432-0843
224 schema:name Cancer Chemotherapy and Pharmacology
225 schema:publisher Springer Nature
226 rdf:type schema:Periodical
227 sg:person.01036404665.54 schema:affiliation grid-institutes:grid.15444.30
228 schema:familyName Rha
229 schema:givenName Sun Young
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036404665.54
231 rdf:type schema:Person
232 sg:person.010673374672.49 schema:affiliation grid-institutes:grid.15444.30
233 schema:familyName Ahn
234 schema:givenName Joong Bae
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673374672.49
236 rdf:type schema:Person
237 sg:person.011321544242.27 schema:affiliation grid-institutes:grid.15444.30
238 schema:familyName Shin
239 schema:givenName Sang Joon
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011321544242.27
241 rdf:type schema:Person
242 sg:person.01276364570.14 schema:affiliation grid-institutes:grid.15444.30
243 schema:familyName Jeung
244 schema:givenName Hei-Cheul
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276364570.14
246 rdf:type schema:Person
247 sg:person.013035643562.16 schema:affiliation grid-institutes:grid.15444.30
248 schema:familyName Cho
249 schema:givenName Byoung Chul
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013035643562.16
251 rdf:type schema:Person
252 sg:person.01363365111.85 schema:affiliation grid-institutes:grid.15444.30
253 schema:familyName Choi
254 schema:givenName Hye Jin
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363365111.85
256 rdf:type schema:Person
257 sg:person.016554426212.74 schema:affiliation grid-institutes:grid.15444.30
258 schema:familyName Chung
259 schema:givenName Hyun Cheol
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554426212.74
261 rdf:type schema:Person
262 sg:person.0767622633.82 schema:affiliation grid-institutes:grid.15444.30
263 schema:familyName Roh
264 schema:givenName Jae Kyung
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767622633.82
266 rdf:type schema:Person
267 sg:pub.10.1038/sj.bjc.6601676 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008836493
268 https://doi.org/10.1038/sj.bjc.6601676
269 rdf:type schema:CreativeWork
270 sg:pub.10.1038/sj.bjc.6603095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042162349
271 https://doi.org/10.1038/sj.bjc.6603095
272 rdf:type schema:CreativeWork
273 grid-institutes:grid.15444.30 schema:alternateName Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea
274 schema:name Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, 134, Shinchon-Dong, Seodaemun-Ku, 120-752, Seoul, South Korea
275 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...